OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Bekaii-Saab on the Impact of Regorafenib in CRC

February 23rd 2018

Tanios Bekaii-Saab, MD, professor of medicine, Mayo Clinic, discusses the impact of regorafenib (Stivarga) on the treatment of patients with colorectal cancer (CRC).

Dr. Perl Discusses Upcoming CAR T-Cell Therapies for ALL

February 23rd 2018

Alexander E. Perl, MD, associate professor of medicine, University of Pennsylvania, discusses upcoming chimeric antigen receptor (CAR) T-cell therapies for patients with acute lymphoblastic leukemia (ALL).

Dr. Kambhampati on Venetoclax in Patients With Myeloid Malignancies

February 23rd 2018

Suman Kambhampati, MD, co-medical director, Blood Cancer Program, Sarah Cannon Cancer Institute, discusses the impact of single-agent venetoclax (Venclexta) in patients with myeloid malignancies.

Dr. Donnellan on Developing Combinations in AML

February 23rd 2018

William B. Donnellan, MD, investigator, Hematologic Malignancies, Sarah Cannon Research Institute, Tennessee Oncology, discusses combinations in light of newly FDA-approved agents in acute myeloid leukemia (AML).

Dr. Mason on the Reliability of the PD-L1 Biomarker

February 22nd 2018

David P. Mason, MD, chief, Thoracic Surgery and Lung Transplantation, Baylor Scott & White Center for Thoracic Surgery, discusses the reliability of the PD-L1 biomarker in non–small cell lung cancer (NSCLC) and its potential applications in surgical approaches.

Dr. Konduri Addresses Unanswered Questions in NSCLC

February 22nd 2018

Kartik Konduri, MD, co-medical director of the Lung Cancer Center of Excellence, Baylor Charles A. Sammons Cancer Center, Baylor University Medical Center, discusses lingering questions in patients with non–small cell lung cancer (NSCLC).

Dr. Chau on Analysis of Asian and Western Patients With Gastric/GEJ Cancer

February 22nd 2018

Ian Chau, MD, consultant medical oncologist, Royal Marsden Hospital, discusses an analysis of Asian and Western patients with chemotherapy-refractory gastric/gastroesophageal junction (GEJ) cancer.

Dr. Wise Discusses Challenges With Immunotherapy in Prostate Cancer

February 22nd 2018

David R. Wise, MD, PhD, assistant professor, Department of Medicine, assistant professor, Department of Urology, NYU Langone's Perlmutter Cancer Center, discusses challenges with immunotherapy in prostate cancer.

Dr. Borgen Discusses HER2 Blockade in Breast Cancer

February 22nd 2018

Patrick Borgen, MD, chair, Department of Surgery, director, Breast Center, Maimonides Medical Center, discusses HER2 blockade in the treatment of patients with HER2-positive breast cancer.

Dr. Bauml on HPV Vaccination for Head and Neck Cancer

February 22nd 2018

Joshua Bauml, MD, assistant professor, Perelman School of Medicine, University of Pennsylvania, discusses HPV vaccination for patients with HPV-related head and neck cancer.

Dr. Ruan Discusses BTK Inhibitors in MCL

February 22nd 2018

Jia Ruan, MD, PhD, associate professor of clinical medicine, Weill Cornell Medicine/NewYork-Presbyterian Hospital, discusses BTK inhibitors for the treatment of patients with mantle cell lymphoma (MCL).

Dr. Levy Discusses the FLAURA Study in Lung Cancer

February 22nd 2018

Benjamin P. Levy, MD, assistant professor of oncology, clinical director of medical oncology, Johns Hopkins Sidney Kimmel Cancer Center, Johns Hopkins Medicine, discusses the FLAURA study in patients with lung cancer.

Dr. Denham on Hyperprogression in Patients With NSCLC

February 21st 2018

Claude Denham, MD, Baylor Medical Center, discusses the manifestation of hyperprogression in patients with non–small cell lung cancer (NSCLC) who have been treated with immunotherapy.

Dr. Simon on the Impact of Immunotherapy Agents in NSCLC

February 21st 2018

George R. Simon, MD, FACP, FCCP, professor of medicine, The University of Texas MD Anderson Cancer Center, discusses how the introduction of immunotherapy in the treatment of patients with locally advanced, stage III non–small cell lung cancer (NSCLC) has affected prognosis.

Dr. Gomella on the FDA Approval of Apalutamide for Nonmetastatic CRPC

February 20th 2018

Leonard Gomella, MD, professor, chair, Department of Oncology, director, Sidney Kimmel Cancer Center Network, Thomas Jefferson University Hospital, discusses the FDA approval of apalutamide (Erleada) for the treatment of patients with nonmetastatic castration-resistant prostate cancer.

Dr. Overman on Remaining Questions With Immunotherapy in CRC

February 20th 2018

Michael J. Overman, MD, associate professor, Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses the remaining questions with immunotherapy in colorectal cancer.

Dr. Sonpavde on Novel Prognostic Marker for Atezolizumab in Bladder Cancer

February 20th 2018

Guru Sonpavde, MD, director of Bladder Cancer at Dana-Farber Cancer Institute, discusses a novel prognostic marker for patients with advanced bladder cancer being treated with the PD-L1 inhibitor atezolizumab (Tecentriq).

Autologous Stem Cell Transplantation in Multiple Myeloma

February 20th 2018

Phyllis McKiernan, a nurse practitioner at John Theurer Cancer Center, Hackensack Medical Center, discusses the outcomes of a study investigating autologous stem cell transplantation (ASCT) in elderly patients with multiple myeloma.

Dr. Pishvaian on the Future of Entrectinib in Pancreatic Cancer

February 20th 2018

Michael Pishvaian, MD, PhD, director, Phase I Clinical Program, co-director of the Ruesch Center Pancreatic Cancer Program Medical Oncology, Otto J. Ruesch Center for the Cure of Gastrointestinal Cancer, Georgetown-Lombardi Comprehensive Cancer Center, discusses the future of entrectinib in the treatment of patients with pancreatic cancer.

Dr. Barrientos Discusses Combination Strategies in CLL

February 20th 2018

Jacqueline C. Barrientos, MD, associate professor, The Feinstein Institute for Medical Research, Northwell Health, discusses the impact of recent combination trials for patients with chronic lymphocytic leukemia (CLL).